MedicaidAdministrativeLow impact
***June 2024 DUR Board Newsletter*** PDF
Connecticut Medicaid (HUSKY Health)·CT · Hematology, Oncology, Pediatrics +2 more·Provider Bulletin
We identified it
Jun 20, 2026
Summary
This is an educational newsletter about Sickle Cell Disease management and treatment options, including hydroxyurea as first-line therapy and newer medications like L-glutamine, crizanlizumab, and voxelotor. It provides clinical background but does not establish new billing requirements or policy changes.
Action Required
No immediate billing action required. This is an informational clinical newsletter about SCD treatment options. Billing teams should be aware of these medications for potential prior authorization requests but no system updates are mandated.